Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives
March 3rd 2021Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.
Investigators find genetic factors may influence diabetic eye disease
March 1st 2021Study results, including data from approximately 42,000 eyes, found diabetic retinopathy severity is a risk factor for diabetic eye disease progression. Other findings support the idea that genetic factors may influence the development of proliferative diabetic retinopathy versus diabetic macular oedema.
Navigating COVID-19 with ophthalmic patients in the hospital setting
February 22nd 2021Experience at one ophthalmic practice in Bulgaria demonstrates that new operating procedures, technologies and good management can enable clinics to remain open and operate safely during the COVID-19 pandemic. Ophthalmic training and education should continue to be a priority.
Biophytis expands patient recruitment for part II of COVA Study in France, Belgium
February 17th 2021Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.
Investigators explore pathogenic cytokines as biomarkers for DMO
January 27th 2021Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.
Non-linear aspheric corneal ablation can be used to treat presbyopia
January 18th 2021Presbyopia can be treated in emmetropic, myopic and hyperopic patients with refractive errors between +5.75 and -9.00 D using corneal non-linear aspheric ablation profiles to increase the depth of field in both eyes, in combination with micro-monovision. Patient satisfaction with this approach is high.
Risks and management of diabetic retinopathy in paediatric patients
January 13th 2021Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.
YAG-shots in IOLs: Safe or dangerous?
December 7th 2020Poorly focused YAG shots lead irrevocably to a permanent defect in the IOL material and thus to possible effects on the quality of vision with straylight or glare. In a recent study, the differing amounts of damage that Nd:YAG causes in a range of hydrophilic and hydrophobic acrylic lens materials was assessed.
AAO: Drop-free prophylaxis regimen before cataract surgery lowers treatment burden with caveats
November 15th 2020During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.
AAO: Fingolimod for MS offers disease control with no development of uveitis
November 15th 2020Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
The importance of recognising Charles Bonnet syndrome in children
November 15th 2020A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.